Bracing for “good results,” the Department of Science and Technology (DOST) said Thursday, Oct. 21, that the drug developers and the public are expected to benefit from the country’s clinical trials seeking to assess the efficacy, safety, and effect on viral clearance of anti-parasitic drug...